New developments in the management of severe skin and deep skin structure infections – focus on tedizolid

Tedizolid, a novel oxazolidinone, is approved for treatment of acute bacterial skin and skin structure infections (ABSSSIs). Tedizolid offers several potential advantages over current ABSSSI treatment options. First, tedizolid has a prolonged half-life, which allows for once-daily dosing. Second, te...

Descripción completa

Detalles Bibliográficos
Autores principales: Durkin, Michael J, Corey, G Ralph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4447168/
https://www.ncbi.nlm.nih.gov/pubmed/26045667
http://dx.doi.org/10.2147/TCRM.S64553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4447168/
https://www.ncbi.nlm.nih.gov/pubmed/26045667
http://dx.doi.org/10.2147/TCRM.S64553

Ejemplares similares